首页> 外文会议>NATO Advanced Study Institute on Vascular Endothelium : Mechanisms of Cell Signaling >Tissue Inhibitor of Metalloproteinase-4 in Human Breast Cancer and Endothelial Cells
【24h】

Tissue Inhibitor of Metalloproteinase-4 in Human Breast Cancer and Endothelial Cells

机译:人乳腺癌和内皮细胞中金属蛋白酶-4的组织抑制剂

获取原文

摘要

Angiogenesis is a fundamental process by which new capillaries are formed from preexisting blood vessels and it plays a very important role in both normal and pathological processes such as coronary collateral circulation, cancer growth, invasion, and metastasis, and rheumatic diseases. Angiogenesis requires breakdown of the extracellular matrix (ECM) by proteinases. Angiogenic switching is accompanied by up-regulation of matrix metalloproteinase (MMP) bioactivity and down-regulation of tissue inhibitors of metalloproteinases (TIMPs). The TIMP family may regulate ECM turnover and tissue remodeling by forming tight binding inhibitory complexes with MMPs. Recently, tissue inhibitor of metalloproteinase-4 (TIMP-4) has been reported. TIMP-4 may inhibit breast cancer cell invasion and angiogenesis. The kinetic studies of the inhibition of the MMPs by recombinant TIMP-4 protein (rTIMP-4p) was performed in a continuous fluorimetric assay with a quenched fluorescent peptide substrate. The inhibition kinetics of rTIMP-4p were analyzed against human fibroblast collagenase (MMP-1), human fibroblast gelatinase A (MMP-2), human fibroblast stromelysin (MMP-3), matrilysin (MMP-7), and human neutrophil gelatinase B (MMP-9). The inhibitor concentrations that inhibited 50% of MMP activities (IC50) were determined to be 19, 3, 45, 8, and 83 nM for MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, respectively. Therefore, TIMP-4 is a potent inhibitor of all five MMPs tested and it has preference for MMP-2 and MMP-7. We have also prepared polyclonal and specific antibody directed against an unique peptide sequence of TIMP-4. This antibody has been characterized in TIMP-4 transfected human breast cancer cell line, MDA-MB-435. Our preliminary studies have also demonstrated that human endothelial cells (HUV-EC-C and ECV304) produce pro-MMP2 pro-MMP9, and MT1-MMP, as well as TIMP-4. The expression and function of TIMP-4 during angiogenesis are under investigation.
机译:血管生成是一种基本过程,通过预先存在的血管形成新的毛细血管,并且在正常和病理过程中起着非常重要的作用,如冠心侧循环,癌症生长,侵袭和转移以及风湿性疾病。血管生成需要通过蛋白酶进行细胞外基质(ECM)的分解。血管生成切换伴随着基质金属蛋白酶(MMP)生物活性的上调和金属蛋白酶组织抑制剂的下调(TIMPS)。 TIMP系列可以通过形成具有MMP的紧密结合抑制络合物来调节ECM营业额和组织重塑。最近,已经报道了金属蛋白酶-4(TIMP-4)的组织抑制剂。 TIMP-4可以抑制乳腺癌细胞侵袭和血管生成。通过重组TiMP-4蛋白(RTIMP-4P)在连续的荧光肽基质中进行重组型蛋白质(RTIMP-4P)的动力学研究。针对人成纤维细胞胶原酶(MMP-1),人成纤维细胞凝胶酶A(MMP-2),人成纤维细胞基团(MMP-3),rolilysin(MMP-7)和人性嗜胞蛋白(MMP-7)和人氏体粒细胞明胶酶B进行抑制动力学(MMP-9)。抑制50%MMP活性(IC 50)的抑制剂浓度为MMP-1,MMP-2,MMP-3,MMP-7和MMP-9的19,3,45,8和83nm,分别。因此,TIMP-4是测试所有五个MMP的有效抑制剂,并且它偏好MMP-2和MMP-7。我们还制备了针对TIMP-4独特的肽序列的多克隆和特异性抗体。该抗体的特征在于TIMP-4转染的人乳腺癌细胞系MDA-MB-435。我们的初步研究还证明,人类内皮细胞(HUV-EC-C和ECV304)生产Pro-MMP2 Pro-MMP9和MT1-MMP,以及TIMP-4。血管生成期间TIMP-4的表达和功能在调查中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号